sirolimus (STN1010904) / Santen, ActualEyes - LARVOL DELTA

PHANTOM: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (clinicaltrials.gov) - P2 | N=86 | Completed | Sponsor: Santen Inc. | Active, not recruiting ➔ Completed

Trial completion • Ophthalmology • Transplantation

PHANTOM: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Santen Inc. | Recruiting ➔ Active, not recruiting | Phase classification: P2a ➔ P2 | Trial completion date: Mar 2025 ➔ May 2025 | Trial primary completion date: Mar 2025 ➔ May 2025

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Ophthalmology • Transplantation

Sirolimus DEB: rationale and promise in CLTI (IM Endo Forum)

Forum

Selective Oral AURKA Inhibitor Treatment for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT: Single-arm Phase 1 Dose Escalation Trial (HMP Global) - "At the 65th American Society of Hematology (ASH) Annual Meeting, Shernan G Holtan, MD...discusses a phase 1 dose escalation portion of a first-in-human clinical trial of post-transplant cyclophosphamide (PTCy) plus sirolimus and selective oral AURKA inhibitor VIC-1911 for graft-versus-host disease (GVHD) and relapse prophylaxis after myeloablative allogeneic hematopoietic cell transplantation (alloHCT)."

Video

Treatment Selection and Sequencing for Chronic Graft Versus Host Disease : Episode 4 : Frontline Treatment Options for Chronic GVHD (Cancer Network) - "The panel reviews treatment approaches for graft-versus-host disease when steroids are not an option and explains how the heterogeneity of GVHD makes finding the right treatment challenging."

Video

12-Month Results From the SWING Multicentre Study: A Novel Sirolimus-Coated Balloon for Use Below-the-Knee (Vascular Disease Management) - "Dr. Ramon Varcoe...presented results from SWING, a prospective, multicenter, single-arm, feasibility study that evaluated the safety and performance of a sirolimus-coated balloon."

Media quote

PHANTOM: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (clinicaltrials.gov) - P2a | N=80 | Recruiting | Sponsor: Santen Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology • Transplantation